According to the deep-dive market assessment study by Growth+ Reports, the global Influenza Medication market peaked at ~US$ 990 million in 2021. The market is expected to witness a CAGR of ~4.8 % from 2022 to 2030.
Treatment for flu or influenza includes a wide variety of medications and therapies. The treatments may either target the influenza virus or relieve the symptoms of the disease. The global influenza medication market is expected to witness growth due to an increase in the incidence of influenza, growing research activities for drug development, and high expenditure on public health. Increased technological advancements that result in novel medications may present this market with a growth opportunity. However, the growing use of influenza vaccines may stifle growth in the global medication market.
The increased case of influenza is mainly due to weak immune systems and the high transmission rate. Also, people with a BMI (Body Mass Index) of 40 or more are at increased risk of getting affected by this disease, as being overweight impairs the immune system by altering the cellular immune system. The geriatric population is also at risk of getting infected by this disease because people 65 or above often have weak immune systems and are more likely to get infected. Furthermore, the influenza virus is prone to mutation, making it difficult to distinguish.
The increased research and development of influenza medication resulted in many new anti-influenza drugs on the market. These drugs are therapeutically and economically beneficial to the consumer. Antivirals offer reasonable control of seasonal flu infection. The U.S. FDA recommends four major antiviral medications, i.e., rapivab or peramivir, relenza or zanamivir, telenza or oseltamivir phosphate, xofluza or baloxavir marboxil. Before these, there were two highly prescribed antiviral drugs, i.e., amantadine and rimantadine. But now, many strains of influenza, including the H1N1 influenza virus, are resistant to these drugs.
The global influenza medication market is divided into four regions: North America, Europe, Asia Pacific, and the Rest of the World. North America holds most of the global influenza medication market share. The high prevalence of influenza increased research and development in this area. A large geriatric population that is more susceptible to flu due to a weakened immune system is driving the market growth in this region. Furthermore, the CDC reports that between 2019 and 2020, nearly 35,000,000 people in the United States experienced symptomatic illness; 16,000,000 sought medical attention, and 18,000 to 80,000 died from influenza. The Asia Pacific has the world's second-largest share of the influenza medication market. Influenza's high prevalence, government initiatives for the control of influenza, and the proliferation of generic antivirals are the factors influencing the growth of the Asia Pacific market.
According to the World Health Organization (WHO), H5N6 influenza type A has caused 52 human infections in the Asia Pacific region since 2014. Half of those infected in 2021 had a close relationship with poultry. The forecast period also shows significant growth potential in Europe due to an increased incidence rate and a growing geriatric population more susceptible to influenza. According to an estimate by the European Centers for Disease Prevention and Control (ECDC), influenza has seasonal implications. Each year, the Europeans experience 4 - 50 million symptomatic infections, and 15,000-70,000 European citizens die from influenza-related causes.
This report entails a thorough quantitative analysis of the trends from 2022 to 2030 in the influenza medication market. This market has been analyzed from four perspectives: treatment type, influenza type, distribution channel, and region. The treatment type is further divided into oseltamivir phosphate, baloxavir marboxil, and others. The influenza type is further grouped into influenza A, and influenza B; according to the distribution channel. The global influenza medication market is classified into hospital, online, and retail pharmacies.
Sanofi S.A, Lupin Limited, Teva Pharmaceutical Industries Ltd., Shionogi & Co. Ltd, Macleods Pharmaceutical Ltd., Alvogen Pvt. Ltd., AstraZaneca Plc., BioCryst Pharmaceuticals Inc., F. Hoffman La Roche Ltd., Novartis AG, and Vitaris AG among others.